Compare IBCP & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBCP | IRWD |
|---|---|---|
| Founded | 1864 | 1998 |
| Country | United States | United States |
| Employees | 270 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 829.6M | 713.8M |
| IPO Year | 2010 | 2009 |
| Metric | IBCP | IRWD |
|---|---|---|
| Price | $35.48 | $4.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $37.00 | $7.67 |
| AVG Volume (30 Days) | 127.2K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | 3.48 | ★ 1400.00 |
| EPS | ★ 1.72 | 0.55 |
| Revenue | $32,075,000.00 | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | $8.98 | $4.39 |
| P/E Ratio | $20.71 | ★ $8.34 |
| Revenue Growth | 0.30 | ★ 8.88 |
| 52 Week Low | $29.83 | $1.26 |
| 52 Week High | $39.24 | $5.78 |
| Indicator | IBCP | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Independent Bank Corp. operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers. The firm's principal markets are the rural and suburban communities across Lower Michigan. The firm generates the majority of its revenue from Interest and fees on loans.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.